藥易購(300937.SZ):擬新設全資子公司 實施藥易購跨境醫貿總部項目
格隆匯6月26日丨藥易購(300937.SZ)公佈,為積極探索開展跨境電商零售進口藥品模式,打造藥易購跨境醫貿總部、構建數智醫藥大健康產業鏈新生態,公司及全資子公司海南藥易購生物科技有限公司(曾用名:海南美迪康生物科技有限公司,簡稱“海南藥易購”)擬與成都國際鐵路港經濟技術開發區管理委員會簽署《項目投資協議》,公司擬以貨幣出資的方式投資人民幣2000萬元,由海南藥易購在成都市青白江區新設一家全資子公司成都藥易購供應鏈有限責任公司(暫定名,具體名稱以工商登記為準)作為推進主體實施藥易購跨境醫貿總部項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.